- Home
- DHIL vs CRVS Comparison
DHIL vs CRVS Comparison
Compare DHIL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- CRVS
- Stock Information
- Founded
- DHIL 1990
- CRVS 2014
- Country
- DHIL United States
- CRVS United States
- Employees
- DHIL N/A
- CRVS N/A
- Industry
- DHIL Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- CRVS Health Care
- Exchange
- DHIL Nasdaq
- CRVS Nasdaq
- Market Cap
- DHIL 392.1M
- CRVS 459.0M
- IPO Year
- DHIL 1995
- CRVS 2016
- Fundamental
- Price
- DHIL $141.40
- CRVS $5.95
- Analyst Decision
- DHIL
- CRVS Strong Buy
- Analyst Count
- DHIL 0
- CRVS 4
- Target Price
- DHIL N/A
- CRVS $15.00
- AVG Volume (30 Days)
- DHIL 25.5K
- CRVS 547.2K
- Earning Date
- DHIL 11-03-2025
- CRVS 11-11-2025
- Dividend Yield
- DHIL 4.24%
- CRVS N/A
- EPS Growth
- DHIL 21.42
- CRVS N/A
- EPS
- DHIL 17.58
- CRVS N/A
- Revenue
- DHIL $151,281,009.00
- CRVS N/A
- Revenue This Year
- DHIL N/A
- CRVS N/A
- Revenue Next Year
- DHIL N/A
- CRVS N/A
- P/E Ratio
- DHIL $8.02
- CRVS N/A
- Revenue Growth
- DHIL 6.29
- CRVS N/A
- 52 Week Low
- DHIL $122.32
- CRVS $2.54
- 52 Week High
- DHIL $173.25
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- DHIL 45.31
- CRVS 60.32
- Support Level
- DHIL $139.55
- CRVS $5.64
- Resistance Level
- DHIL $143.00
- CRVS $6.09
- Average True Range (ATR)
- DHIL 2.41
- CRVS 0.34
- MACD
- DHIL -0.24
- CRVS -0.04
- Stochastic Oscillator
- DHIL 26.36
- CRVS 65.80
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).